AstraZeneca PLC
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
- Full Time Employees
- 94,300
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge United Kingdom CB2 0AA
- IPO Date
- May 12, 1993
- CIK
- 0000901832
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Company News
Trump Says Pharmaceutical Tariffs Coming in Near Future
Trump says US pharma tariffs coming in not-too-distant future
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis
Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
Explainer: Prescription drugs become a target in Trump's trade war
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
3 No-Brainer Growth Stocks to Buy for Less Than $100
Trump inflicts a £9bn blow to the UK drug sector with tariff threat
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy
Live Nasdaq Composite: FIVE Falls, AZN and PEP Rise From Tariff Ashes